Status: Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Participants needed: 120
Trial details
Phase: Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jun 8, 2026Locations: 93
Eligibility criteria
Reasonable exclusion of tumor or malignancy before baseline visit (randomization... [+8]
Any untreated teratoma or thymoma at baseline visit (randomization) [+32]